Literature DB >> 22950597

Proposal of a histopathological predictive rule for the differential diagnosis between American tegumentary leishmaniasis and sporotrichosis skin lesions.

L P Quintella1, S R L Passos, L H M de Miranda, T Cuzzi, M B de L Barros, A C Francesconi-do-Vale, M C G Galhardo, M de F Madeira, M H Figueiredo de Carvalho, A de O Schubach.   

Abstract

BACKGROUND: American tegumentary leishmaniasis (ATL) and sporotrichosis exhibit similar histopathology and low frequencies of microorganism detection.
OBJECTIVES: This study seeks to identify microscopic alterations that can distinguish between these diseases.
METHODS: Haematoxylin and eosin stained slides of 171 ATL and 97 sporotrichosis samples from active cutaneous lesions were examined for histopathological alterations. The lesions were diagnosed by isolating the agent (which was not visible) in culture. An intuitive diagnosis was assigned to each slide. The strength of the association between the histopathological findings and the diagnosis was estimated by an odds ratio, and each finding was graded according to a regression model. A score was assigned to each sample based on the histopathological findings. A study of the interobserver reliability was performed by calculating kappa coefficients of the histopathological findings and intuitive diagnoses.
RESULTS: The markers 'macrophage concentration', 'tuberculoid granuloma' and 'extracellular matrix degeneration' were associated with ATL. 'Suppurative granuloma', 'stellate granuloma', 'different types of giant cells', 'granulomas in granulation tissue' and 'abscess outside the granuloma' were associated with a diagnosis of sporotrichosis. 'Macrophage concentration' and 'suppurative granuloma' had the highest (substantial and almost perfect, respectively) reliability. The regression model score indicated 92.0% accuracy. The intuitive diagnosis had 82.5% diagnostic accuracy and substantial reliability.
CONCLUSIONS: Taking into account the clinical and epidemiological context, some histopathological alterations might be useful for the differential diagnosis between ATL and sporotrichosis cutaneous lesions in cases in which the aetiological agent is not visible.
© 2012 The Authors. BJD © 2012 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2012        PMID: 22950597     DOI: 10.1111/j.1365-2133.2012.11012.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  6 in total

Review 1.  Immunopathogenesis of Human Sporotrichosis: What We Already Know.

Authors:  Fatima Conceição-Silva; Fernanda Nazaré Morgado
Journal:  J Fungi (Basel)       Date:  2018-07-31

Review 2.  The Binomial Parasite-Host Immunity in the Healing Process and in Reactivation of Human Tegumentary Leishmaniasis.

Authors:  Fatima Conceição-Silva; Jessica Leite-Silva; Fernanda N Morgado
Journal:  Front Microbiol       Date:  2018-06-19       Impact factor: 5.640

3.  Severe mucosal leishmaniasis with torpid and fatal evolution.

Authors:  Jesús Rojas Jaimes
Journal:  Clin Case Rep       Date:  2022-08-14

Review 4.  Current Progress on Epidemiology, Diagnosis, and Treatment of Sporotrichosis and Their Future Trends.

Authors:  Anderson Messias Rodrigues; Sarah Santos Gonçalves; Jamile Ambrósio de Carvalho; Luana P Borba-Santos; Sonia Rozental; Zoilo Pires de Camargo
Journal:  J Fungi (Basel)       Date:  2022-07-26

5.  Effect of secondary infection on epithelialisation and total healing of cutaneous leishmaniasis lesions.

Authors:  Liliane de Fátima Antonio; Marcelo Rosandiski Lyra; Maurício Naoto Saheki; Armando de Oliveira Schubach; Luciana de Freitas Campos Miranda; Maria de Fátima Madeira; Maria Cristina da Silva Lourenço; Aline Fagundes; Érica Aparecida Dos Santos Ribeiro; Leonardo Barreto; Maria Inês Fernandes Pimentel
Journal:  Mem Inst Oswaldo Cruz       Date:  2017-09       Impact factor: 2.743

Review 6.  An 18-year-old man with tropical verrucous syndrome: Leishmaniasis or sporotrichosis?

Authors:  Paola Macías; Juliana Ordóñez; Claudia M Arenas; Gerzaín Rodríguez
Journal:  Biomedica       Date:  2021-06-29       Impact factor: 0.935

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.